

DRAFT ANNOTATED AGENDA

FORTY-NINTH SESSION OF THE JOINT COORDINATING BOARD

17–18 June 2026, Executive Board (EB) room, Building A, WHO headquarters, Geneva, Switzerland

Documentation is available on the JCB website at:
<https://tdr.who.int/groups/joint-coordinating-board/jcb49-documents>

Enquiries may be sent to jcb@who.int

*Unless otherwise indicated, sessions will be held in the Executive Board (EB) room, Building A.
Simultaneous interpretation will be provided in English, French and Spanish.*

PRE-MEETING DAY, Tuesday, 16 June 2026

Any time	BADGE COLLECTION – MAIN BLDG RECEPTION (PARTICIPANTS MUST BE REGISTERED IN CVENT) Please consider arriving early to avoid the queues.
-----------------	---

14:00	REFRESHMENTS
--------------	---------------------

14:30–16:00	Briefing session
--------------------	-------------------------

Salle T, Building B (via the main reception). Refreshments will be available from 14:00.
*Introductory briefing for JCB participants, primarily new members, who wish to acquaint themselves with the Programme and the processes and functions of the Board. This is also an opportunity for disease endemic country and resource contributor group members to meet informally should they wish to do so. Interpretation will **not** be provided for this session.*

Wednesday, 17 June 2026

Time	Agenda item	Action / Information	Reference Documents
07:30–08:45	BADGE COLLECTION – MAIN RECEPTION (PARTICIPANTS MUST BE REGISTERED IN CVENT)		
09:00–09:30	1. Welcome and opening remarks <i>Dr Tedros Adhanom Ghebreyesus, WHO Director-General</i> <i>Dr Dirk Mueller, Chair of JCB</i> <i>Dr Meg Doherty, Director, Department of Science for Health, on behalf of the WHO Chief Scientist</i>		
09:30–09:40	2. Statutory business 2.1 Appointment of the rapporteur 2.2 Adoption of the agenda 2.3 Declarations of interests	Appointment of the Rapporteur Adoption of the agenda	Draft Agenda TDR/JCB49/26.1 Draft Annotated Agenda TDR/JCB49/26.1a
09:40–10:40	3. Progress since JCB48 3.1 Director's report <i>Dr Marcus Lacerda, Director, TDR, will present the report, followed by Q&A.</i>	Information	TDR 2025 Annual Report Report of JCB48, June 2025 TDR/JCB48/25.3 Follow-up to the JCB48 decisions and recommendations TDR/JCB49/26.4
			
10:40–11:10	COFFEE BREAK		
11:10–11:25	3.2 Report of the Standing Committee <i>Dr Iris Cazali, JCB Vice-Chair, will report on the Standing Committee's activities since JCB48.</i>	Information	Standing Committee 118 and 119 recommendations TDR/SC118/25.3; TDR/SC119/26.3
11:25–11:40	3.3 Report by the Chair of the TDR Scientific and Technical Advisory Committee (STAC) <i>Professor Margaret Gyapong, Chair of STAC, will present the STAC report.</i>	Information	Report of STAC48 TDR/STAC48/26.3
11:40–12:00	3.4 Programme performance overview - Key performance indicators 2025 - Risk management <i>Dr Michael Mihut, Unit Head, Programme Innovation and Management, will present this item.</i>	Approval	2025 TDR Results Report TDR/JCB49/26.5 TDR Risk Management Report, 2025 TDR/JCB49/26.6
12:00–13:30	LUNCH BREAK		

Wednesday, 17 June 2026 (continued)

Time	Agenda item	Action / Information	Reference Documents
13:30–14:15	4. Financial management report 2024–2025 and outlook 2026–2029 ▪ Financial report 2025 ▪ Outlook 2026–2029 <i>Dr Michael Mihut will present the financial report certified by the WHO Comptroller, the financial outlook 2026–2029 and the financial statement.</i>	Approval	TDR Financial Management Report 2024–2025 and Outlook 2026–2029 TDR/JCB49/26.7 TDR Certified Financial Statement for the year ended 31 December 2025 TDR/JCB49/26.8 TDR investment case
14:15–14:45	5. Update from TDR co-sponsors ▪ UNICEF – Mr Benjamin Schreiber ▪ UNDP – Mrs Luciana Mermet ▪ World Bank – TBC ▪ WHO – Gerardo Zamora Monge	Information	
14:45–15:15	COFFEE BREAK		
15:15–16:30	6. Panel discussion: The evolving global health architecture and TDR's role in the future global health ecosystem <i>This panel discussion will bring together global health leaders to reflect on how the evolving global health architecture is reshaping priorities, partnerships, and governance, and to consider how TDR can continue to contribute as a trusted, transparent, and research-driven actor within the future global health ecosystem.</i> <i>Dr Garry Aslanyan will open the session with a brief overview of the current processes reviewing the global health architecture.</i> <i>Dr Marcus Lacerda will provide concluding comments and reflections.</i> <i>The discussion will feature the following panelists:</i> <i>Dr Jeremy Farrar, Assistant Director-General, Health Promotion, Disease Prevention and Care, WHO</i> <i>Dr Catherine Kyobutungi, Executive Director, African Population and Health Research Center</i> <i>Dr Anders Nordström, Senior Advisor, International Politics and Diplomacy for Health, Karolinska Institutet</i>	Information	

Wednesday, 17 June 2026 (continued)

*Dr Bernard Pécoul, Vice-Chair of the Board,
Global Antibiotic Research & Development
Partnership (GARDP); Founder and former
Executive Director of Drugs for Neglected
Diseases initiative (DNDi)*

*Dr Magda Robalo, President and Co-Founder,
The Institute for Global Health and
Development (IGHD)*

**JCB RECEPTION
from 16:45 – 18:45**

EB reception zone

Thursday, 18 June 2026

Time	Agenda item	Action / Information	Reference Documents
09:00–09:45	Informal meeting of TDR resource contributors (Indian room, next to EB room) Chaired by the RC representative on the JCB, Mr Koen Van Acoleyen (Belgium)		
09:50–10:30	Informal meeting of disease endemic country representatives (EB room) Chaired by the DEC representative on the JCB, Dr Olusola Ayoola (Nigeria) <i>Simultaneous interpretation will be provided in English, French and Spanish.</i>		
10:30–11:00	COFFEE BREAK (outside EB room, A building)		
11:00–12:30	7. Moderated technical session and Q&A <i>Dr Garry Aslanyan, TDR Partnerships and Global Engagement Manager, will moderate this session.</i> <u>Overview and background</u> Strengthening research excellence in the Western Pacific region <i>Presented by Dr Zalilah binti Abdullah, Institute for Health Systems Research (IHSR), National Institutes of Health (NIH), Ministry of Health Malaysia</i> TDR's contribution to a career on research on human African trypanosomiasis in Africa <i>Presented by Dr Wilfried Mutombo Kalonji, Regional Head Of Clinical Operations, Drugs for Neglected diseases Initiative, Democratic Republic of Congo</i> Advancing universal health coverage in Nigeria through social innovation <i>Presented by Dr Ogechukwu Aribodor, Associate Professor, Nnamdi Azikiwe University, Nigeria</i> <i>Presented by Gima Humphrey Forje, Chief Executive Officer, TY Danjuma Foundation, and Ms Eucheria Unimnake, Health Projects Manager, TY Danjuma Foundation, Nigeria</i>	Information	
12:30–14:00	LUNCH BREAK		

Thursday, 18 June 2026 (continued)

Time	Agenda item	Action / Information	Reference Documents
14:00–14:30	8. TDR Governance 8.1 Selection of five members of the JCB according to Paragraph 2.2.1 of the TDR Memorandum of Understanding <i>Dr Garry Aslanyan will present this item.</i>	Selection of JCB members	Note on the membership of the Joint Coordinating Board TDR/JCB49/26.9 Documentation available on the website: - List of JCB members - JCB membership wheel - History of membership on TDR's Joint Coordinating Board, 1978–2026 - Memorandum of Understanding
	8.2 Updates from the informal meetings of the resource contributors and disease endemic country groups	Information	
	8.3 Membership of the Scientific and Technical Advisory Committee (STAC) <i>Dr Garry Aslanyan will present this item.</i>	Endorsement	Proposed STAC membership from 1 July 2026 TDR/JCB49/26.10
14:30–14:35	9. Date and place of JCB50 and JCB51 <i>As agreed at JCB48, JCB50 will be held from 16–17 June 2027 (15 June briefing session) and JCB51 will be held from 21–22 June 2028 (20 June briefing session). Both meetings will be held in Geneva.</i>	Decision	
14:35–15:15	10. Summary of decisions and recommendations <i>The Rapporteur, supported by the Secretariat, will present a summary of the meeting's decisions and recommendations.</i>	Decision	
15:15–15:20	11. Closing session Any other business Concluding remarks <i>Chair of the JCB</i>		
15:20	END-OF-SESSION REFRESHMENTS		